Recombinant Anti-CD3 x Anti-EPCAM Bispecific Antibody (Tandem Diabody) (T-BSDB-079)

Recombinant Anti-CD3 x Anti-EPCAM Bispecific Antibody (Tandem Diabody) is designed to be expressed as a monomeric subunit (single chain Diabody, scDb), with four variable domains from two parental antibodies. Then the two peptide chains can dimerize in a head-to-tail fashion. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & EPCAM

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Solid tumors

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

EPCAM

Gene ID

4072

UniProt ID

P16422

Alternative Names

EPCAM; epithelial cell adhesion molecule; ESA; KSA; M4S1; MK-1; DIAR5; EGP-2; EGP40; KS1/4; MIC18; TROP1; EGP314; HNPCC8; TACSTD1; epithelial glycoprotein 314; human epithelial glycoprotein-2; cell surface glycoprotein Trop-1; adenocarcinoma-associated antigen; tumor-associated calcium signal transducer 1; major gastrointestinal tumor-associated protein GA733-2; membrane component, chromosome 4, surface marker (35kD glycoprotein)

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-EPCAM Bispecific Antibody (Tandem Diabody) (T-BSDB-079). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD3 x Anti-EPCAM Bispecific Antibody (Tandem Diabody) (CAT#: T-BSDB-079)

Specifications

Targets

Customer Reviews and Q&As